1. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis
- Author
-
Valgimigli, Marco, Smits, Pieter C, Frigoli, Enrico, Bongiovanni, Dario, Tijssen, Jan, Hovasse, Thomas, Mafragi, Al, Ruifrok, Willem Theodoor, Karageorgiev, Dimitar, Aminian, Adel, Garducci, Stefano, Merkely, Bela, Routledge, Helen, Ando, Kenji, Diaz Fernandez, Josè Francisco, Cuisset, Thomas, Nesa Malik, Fazila Tun, Halabi, Majdi, Belle, Loic, Din, Jehangir, Beygui, Farzin, Abhyankar, Atul, Reczuch, Krzysztof, Pedrazzini, Giovanni, Heg, Dik, Vranckx, Pascal, MASTER DAPT Investigators, Cardiology, ACS - Heart failure & arrhythmias, Valgimigli, M, Smits, PC, Frigoli, E, Bongiovanni, D, Tijssen, J, Hovasse, T, Mafragi, A, Ruifrok, WT, Karageorgiev, D, Aminian, A, Garducci, S, Merkely, B, Routledge, H, Ando, K, Fernandez, JFD, Cuisset, T, Malik, FTN, Halabi, M, Belle, L, Din, J, Beygui, F, Abhyankar, A, Reczuch, K, Pedrazzini, G, Heg, D, and VRANCKX, Pascal
- Subjects
animal structures ,Aspirin ,Myocardial Infarction ,Hemorrhage ,Percutaneous coronary intervention ,Stroke ,Treatment Outcome ,Complex intervention ,Dual antiplatelet therapy ,Humans ,Drug Therapy, Combination ,Acute Coronary Syndrome ,High bleeding risk ,610 Medizin und Gesundheit ,Cardiology and Cardiovascular Medicine ,Platelet Aggregation Inhibitors - Abstract
Aim To assess the effects of 1- or ≥3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS). Methods and results In the MASTER DAPT trial, 3383 patients underwent non-complex (abbreviated DAPT, n = 1707; standard DAPT, n = 1676) and 1196 complex (abbreviated DAPT, n = 588; standard DAPT, n = 608) PCI. Co-primary outcomes at 335 days were net adverse clinical events [NACE; composite of all-cause death, myocardial infarction, stroke, and bleeding academic research consortium (BARC) 3 or 5 bleeding events]; major adverse cardiac or cerebral events (MACCE; all-cause death, myocardial infarction, and stroke); and Types 2, 3, or 5 BARC bleeding. Net adverse clinical events and MACCE did not differ with abbreviated vs. standard DAPT among patients with complex [hazard ratio (HR): 1.03, 95% confidence interval (CI): 0.69–1.52, and HR: 1.24, 95% CI: 0.79–1.92, respectively] and non-complex PCI (HR: 0.90, 95% CI: 0.71–1.15, and HR: 0.91, 95% CI: 0.69–1.21; Pinteraction = 0.60 and 0.26, respectively). BARC 2, 3, or 5 was reduced with abbreviated DAPT in patients with and without complex PCI (HR: 0.64; 95% CI: 0.42–0.98, and HR: 0.70; 95% CI: 0.55–0.89; Pinteraction = 0.72). Among the 2816 patients with complex PCI and/or ACS, NACE and MACCE did not differ and BARC 2, 3, or 5 was lower with abbreviated DAPT. Conclusion In HBR patients free from recurrent ischaemic events at 1 month, DAPT discontinuation was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of PCI or patient complexity. Clinical Trial Registration This trial is registered with ClinicalTrials.gov, number NCT03023020, and is closed to new participants, with follow-up completed.
- Published
- 2022